Profile data is unavailable for this security.
About the company
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
- Revenue in USD (TTM)5.92m
- Net income in USD-75.79m
- Incorporated2015
- Employees62.00
- LocationBIOAGE Labs Inc5885 Hollis Street, Suite 370EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 806-1445
- Websitehttps://bioagelabs.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arvinas Inc | 312.30m | -58.50m | 760.09m | 430.00 | -- | 1.48 | -- | 2.43 | -0.8048 | -0.8048 | 4.30 | 7.97 | 0.3105 | -- | 22.63 | 726,279.10 | -5.82 | -20.58 | -7.36 | -25.05 | -- | -- | -18.73 | -211.50 | -- | -- | 0.0007 | -- | 235.54 | 43.71 | 45.85 | -- | -22.02 | -- |
| SS Innovations International Inc | 33.57m | -17.11m | 760.93m | 378.00 | -- | 19.19 | -- | 22.66 | -0.0959 | -0.0959 | 0.1822 | 0.2048 | 0.6253 | 1.19 | 5.09 | 88,820.32 | -31.86 | -77.47 | -50.87 | -137.45 | 48.25 | 23.69 | -50.96 | -169.09 | 1.34 | -- | 0.2025 | -- | 251.46 | -- | 8.27 | -- | 67.53 | -- |
| Kalvista Pharmaceuticals Inc | 15.12m | -210.31m | 764.26m | 270.00 | -- | 44.96 | -- | 50.55 | -3.95 | -3.95 | 0.2838 | 0.3363 | 0.0604 | -- | 1.51 | 55,992.59 | -84.00 | -49.86 | -97.02 | -54.21 | 87.95 | -- | -1,391.14 | -- | 7.21 | -82.77 | 0.9412 | -- | -- | -- | -44.85 | -- | 33.39 | -- |
| Bicara Therapeutics Inc | 0.00 | -121.52m | 770.23m | 55.00 | -- | 1.91 | -- | -- | -5.03 | -5.03 | 0.00 | 7.38 | 0.00 | -- | -- | 0.00 | -25.61 | -- | -26.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.80 | -- | -- | -- |
| Arbutus Biopharma Corp | 14.61m | -42.28m | 771.22m | 44.00 | -- | 9.95 | -- | 52.80 | -0.2219 | -0.2219 | 0.0764 | 0.4032 | 0.1227 | -- | 11.62 | 331,954.50 | -35.50 | -44.03 | -39.50 | -49.46 | -- | -- | -289.45 | -433.59 | -- | -- | 0.0454 | -- | -65.98 | 0.5268 | 4.02 | -- | -20.93 | -- |
| Maravai Lifesciences Holdings Inc | 192.28m | -121.24m | 772.23m | 550.00 | -- | 3.14 | -- | 4.02 | -0.8442 | -0.8442 | 1.34 | 0.961 | 0.1808 | 3.18 | 7.48 | 337,338.60 | -20.14 | 8.27 | -27.68 | 10.45 | 20.86 | 72.61 | -111.42 | 25.48 | 4.56 | -7.37 | 0.4288 | 0.00 | -10.30 | 12.61 | -21.69 | -- | 12.69 | -- |
| MapLight Therapeutics Inc | 0.00 | -92.43m | 781.32m | 109.00 | -- | -- | -- | -- | -2.23 | -2.23 | 0.00 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.26 | -- | -- | -- |
| Janux Therapeutics Inc | 10.00m | -101.90m | 789.74m | 74.00 | -- | 0.8084 | -- | 78.97 | -1.67 | -1.67 | 0.1649 | 16.24 | 0.0116 | -- | -- | 135,135.10 | -11.85 | -13.75 | -12.17 | -14.23 | -- | -- | -1,018.95 | -743.21 | -- | -- | 0.00 | -- | 30.99 | -- | -18.36 | -- | -- | -- |
| Omeros Corp | 0.00 | -121.24m | 811.10m | 202.00 | -- | -- | -- | -- | -2.04 | -2.02 | 0.00 | -3.15 | 0.00 | -- | -- | 0.00 | -48.59 | -50.90 | -66.86 | -63.20 | -- | -- | -- | -- | -- | -- | 2.72 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| Xencor Inc | 167.36m | -138.75m | 829.79m | 250.00 | -- | 1.33 | -- | 4.96 | -1.88 | -1.88 | 2.26 | 8.76 | 0.1807 | -- | 10.46 | 669,428.00 | -15.07 | -9.89 | -16.65 | -10.95 | -- | -- | -83.42 | -48.58 | -- | -12.12 | 0.1755 | -- | -36.72 | -6.75 | -74.73 | -- | -2.93 | -- |
| BIOAGE Labs Inc | 5.92m | -75.79m | 832.44m | 62.00 | -- | 2.58 | -- | 140.69 | -2.04 | -2.04 | 0.1594 | 7.74 | 0.0184 | -- | -- | 95,435.48 | -23.59 | -- | -25.31 | -- | -- | -- | -1,280.90 | -- | -- | -- | 0.0147 | -- | -- | -- | -11.36 | -- | -- | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 870.86m | 162.00 | -- | 5.90 | -- | 6.10 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Evommune Inc | 3.00m | -66.26m | 878.89m | 45.00 | -- | -- | -- | 292.96 | -2.20 | -2.20 | 0.0997 | 2.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2,158.80 | -- | -- | -- | 0.0086 | -- | 40.00 | -- | -100.59 | -- | -- | -- |
| AbCellera Biologics Inc | 35.32m | -171.68m | 880.05m | 596.00 | -- | 0.9119 | -- | 24.91 | -0.5765 | -0.5765 | 0.1187 | 3.22 | 0.0257 | -- | 0.97 | 59,268.46 | -12.49 | 2.01 | -13.20 | 2.20 | -- | -- | -486.01 | 10.48 | -- | -- | 0.00 | 0.00 | -24.17 | 19.95 | -11.24 | -- | 81.35 | -- |
| Aktis Oncology Inc | 5.56m | -60.65m | 906.63m | -- | -- | -- | -- | 163.06 | -1.20 | -1.20 | 0.1098 | 3.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,090.81 | -- | -- | -- | 0.00 | -- | -- | -- | -53.56 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to BIOAGE Labs Inc's reporting currency: US Dollar USD
26.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cormorant Asset Management LPas of 30 Sep 2025 | 2.14m | 5.97% |
| Adar1 Capital Management LLCas of 30 Sep 2025 | 1.88m | 5.24% |
| Tang Capital Management LLCas of 30 Sep 2025 | 1.60m | 4.46% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.24m | 3.46% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.14m | 3.19% |
| Geode Capital Management LLCas of 30 Sep 2025 | 562.73k | 1.57% |
| Millennium Management LLCas of 30 Sep 2025 | 306.55k | 0.86% |
| Comprehensive Financial Management LLC (California)as of 30 Sep 2025 | 271.84k | 0.76% |
| Jacobs Levy Equity Management, Inc.as of 30 Sep 2025 | 213.09k | 0.59% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 198.11k | 0.55% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
